Search

Your search keyword '"Schneebaum S"' showing total 152 results
Start Over Author "Schneebaum S"
152 results on '"Schneebaum S"'

1. Identification of Lymph Node Metastases in Recurrent Colorectal Cancer

Author

Schneebaum, S., Troitsa, A., Avital, S., Haddad, R., Kashtan, H., Gitstein, G., Baratz, M., Brazovsky, E., Papo, J., Skornick, Y., Schlag, P. M., editor, Senn, H.-J., editor, Diehl, V., editor, Parkin, D. M., editor, Rajewsky, M. F., editor, Rubens, R., editor, Wannenmacher, M., editor, Schlag, Peter M., editor, and Veronesi, Umberto, editor

Published
2000
Full Text
View/download PDF

3. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Peritoneal Surface Malignancies of Colonic Origin: A Consensus Statement

Author

Esquivel, J., Sticca, R., Sugarbaker, P., Levine, E., Yan, T. D., Alexander, R., Baratti, D., Bartlett, D., Barone, R., Barrios, P., Bieligk, S., Bretcha-Boix, P., Chang, C. K., Chu, F., Chu, Q., Daniel, S., de Bree, E., Deraco, M., Dominguez-Parra, L., Elias, D., Flynn, R., Foster, J., Garofalo, A., Gilly, F. N., Glehen, O., Gomez-Portilla, A., Gonzalez-Bayon, L., Gonzalez-Moreno, S., Goodman, M., Gushchin, V., Hanna, N., Hartmann, J., Harrison, L., Hoefer, R., Kane, J., Kecmanovic, D., Kelley, S., Kuhn, J., LaMont, J., Lange, J., Li, B., Loggie, B., Mahteme, H., Mann, G., Martin, R., Misih, R. A., Moran, B., Morris, D., Onate-Ocana, L., Petrelli, N., Philippe, G., Pingpank, J., Pitroff, A., Piso, P., Quinones, M., Riley, L., Rutstein, L., Saha, S., Alrawi, S., Sardi, A., Schneebaum, S., Shen, P., Shibata, D., Spellman, J., Stojadinovic, A., Stewart, J., Torres-Melero, J., Tuttle, T., Verwaal, V., Villar, J., Wilkinson, N., Younan, R., Zeh, H., Zoetmulder, F., and Sebbag, G.

Published
2007
Full Text
View/download PDF

4. Poster Presentations

Author

Mitra, A., Walker, S. A., Bayer, I., Pickovsky, B., Cohen, S. M., Schmitt, S. L., Lucas, F. L., Wexner, S. D., Szilagy, E. J., Ryan, J. B., Williams, J. G., Deen, K. I., Grant, E., Kumar, D., Wiltz, O. H., Garcia, J. E., Feliciano, R., Martino, J., Solomon, M., McLeod, R. S., O'Connor, B., Steinhart, H., Greenberg, G., Cohen, Z., Meagher, A. P., Adams, W. J., Lubowski, D. Z., Ellis, C. N., Boggs, H. W., Coyle, D. J., Blakemore, W. S., Nahas, S. C., Ibrahim, R. El, Pinotti, H. W., Palakanis, K., DeNobile, J., Sweeney, B., Blankenship, C., Sun, J. H., Stiegmann, G. V., Kim, J. G., Pearlman, N. W., Landes, R. V., Hankin, R. C., Barkel, D. C., Beauregard, W. L., Poulik, M. D., Chen, J. C., Dmuchowski, C., Cho, E., Lee, P. Y., Fletcher, W. S., Sullivan, E. S., Vetto, J. T., Hull, T. L., Lavery, I. C., Saxton, J. P., McCue, J., Sheffield, J., Phillips, R., DiPierro, J., Milsom, J. W., Fazio, V. W., Strong, S. A., Vernava, III, A. M., Longo, W. E., Wade, T. P., Virgo, K. S., Coplin, M. A., Johnson, F. E., Cavina, E., Menconi, C., Ghiselli, G., Seccia, M., Tjandra, J. J., Lowndes, R., McKirdy, H., Schroeder, T., Hughes, L. E., Sentovich, S. M., Rivela, L. J., Thorson, A. G., Blatchford, G. J., Christensen, M. A., Jensen, L. L., Lowry, A. C., Miller, R., Mills, A., Durdey, P., Hock-Saive, D., Lombard, R., Jehaes, C., Markiewicz, S., Penders, L., Fontaine, F., Cusumano, P., Nelissen, G., MacDonald, A., Baxter, J. N., Bessent, R. G., Gray, H. W., Finlay, I. G., Duthie, G. S., Farouk, R., Bartolo, D. C. C., Ramanujam, P. S., Venkatesh, K. S., Oliver, G. C., Vachon, D., Eisenstat, T. E., Rubin, R. J., Salvati, E. P., Dorsey-Tyler, K. R., Harmon, G., Medwell, S. J., Binderow, S. R., Noguerás, J. J., Jagelman, D. G., Decanini, C., Bohm, B., Stolfi, V. W., Cataldo, P. A., Hadick, C., Resnikov, P., Mellinger, J. D., Cunningham, B., Vayer, Jr., A. J., Larach, S. W., Williamson, P. R., Ferrara, A., Salomon, M., Nogueras, J. J., Sullivan, J., Staniunas, R. J., Keck, J. O., Counihan, T., Marcello, P., Barrett, R. C., Oster, M., Roberts, P. L., Schoetz, D. J., Murray, J. J., Veidenheimer, M. C., Coller, J. A., Sagar, P. M., Lewis, W., Williamson, M., Holdsworth, P. J., Johnston, D., Jorge, J. M. N., Morgado, Jr., P. J., James, K., Morgado, Jr., P., Penna, C., Kartheuser, A., Tiret, E., Parc, R., McIntyre, P. B., Pemberton, J. H., Wolff, B. G., Dozois, R. R., Beart, R. W., Kelley, K. A., Harrison, J. B., Hockenberry, S. E., Williamson, M. E. R., Lewis, W. G., Sagar, P., Armstrong, D. N., Collopy, B. C., Ryan, P. J., Fink, R., Mackay, J. R., Woods, R. J., Nazarian, H. K., Kong, L. B., Fleshner, P. R., Keighley, M. R. B., Farmakis, N., Tudor, R., Wiltz, O., Wong, W. D., Goldberg, S. M., Rothenberger, D. A., Arnold, M. W., Schneebaum, S., Martin, Jr., E. W., Young, D. C., Schechter, S., Snyder, M. L., Orkin, B. A., Smith, L. E., Dean, P. A., Ramsey, P. S., Nelson, H., Barker, G., Neoptolomos, J. P., Patel, R. T., Pall, A., and Adu, D.

Published
1993
Full Text
View/download PDF

5. American Society of Colon and Rectal Surgeons 91st Annual Convention Podium and Poster abstracts: June 7–12, 1992 San Francisco, CA

Author

Lechner, P., Lind, P., Binter, G., Golub, R. W., Kerner, B. A., Wise, Jr., W. E., Meesig, D. M., Hartmann, R. F., Khanduja, K. S., Sayre, J. W., Aguilar, P. S., Guillem, J. G., Forde, K. A., Treat, M. R., Neugut, A. I., O'Toole, K. M., Diamond, B. E., Kewenter, J., Brevinge, H., Haglind, E., Limberg, B., Elles, C. N., Boggs, W. H., Slagle, G. H., Cole, P. A., Coyle, D. J., Smith, L. E., Orkin, B., Saclarides, T. J., Sheridan, W. G., Lowndes, R. H., Young, H. L., Wong, W. D., Rothenberger, D. A., Bartolo, D. C. C., Wexner, S. D., Ger, G. C., Jorge, J. M. N., Lee, E., Nogueras, J. J., Jagelman, D. G., McKenna, K., Koltun, W. A., Bute, B., Lichliter, W., Le, T., Timmcke, A., Gathright, J. B., Mascagni, D., Hojo, K., Moriya, Y., Sugihara, K., Di, G., Zenni, G. C., Abraham, K., Dobrin, P. B., Harford, F. J., Suzuki, K., Gunderson, L., Devine, R. M., Dozois, R. R., Cavaliere, F., Pemberton, J. H., Fazio, V., Cosimelli, M., Beart, R. W., Giannarelli, D., Moran, M., Ramos, A., Rothenberger, D., Goldberg, S., Antonenko, D., Heymen, S., Gulledge, A. D., Jakate, S., Saclarides, T., Heine, J. A., Williams, J. G., VanBergen, E. H., Buie, W. D., Goldberg, S. M., Davies, N., Yates, J., Jenkins, S. A., Taylor, B. A., Bapat, B., Stern, H., Berk, T., Parker, J., Ray, P. N., McLeod, R., Cohen, Z., Rowe, J. K., Zera, R. T., Madoff, R. D., Bubrick, M. P., Roberts, J. C., Johnston, G. R., Fenney, D. A., Farouk, R., Duthie, G. S., McCue, J. L., Phillips, R. K. S., Viamonte, M., Cole, J., Gottesman, L., Solomon, M. J., McLeod, R. S., Kern, K., Jensen, L. L., Lowry, A. C., Vernava, III, A. M., Longo, W. E., Daniel, G. L., Ehrenpreis, E., Stone, J. M., Cosman, B. C., Wolfe, V. A., Nino-Murcia, M., Perkash, I., Marcello, P. W., Roberts, P. L., Schoetz, Jr., D. J., Murray, J. J., Coller, J. A., Veidenheimer, M. C., Keighley, M. R. B., Grobler, S. P., Hosie, K. B., Schmitt, S. L., James, K., Lucas, F., Peck, Donald A., Ferrara, A., Grotz, R. L., Perry, R. E., Hanson, R. B., Lewis, W. G., Holdsworth, P. J., Sagar, P. M., Johnston, D., Perry, T. G., Strong, S. A., Fazio, V. W., Lavery, I. C., Oakley, J. R., Church, J. M., Milsom, J. W., Fozard, J. B. J., Nelson, H., Schneebaum, S., Arnold, M. W., Young, D., LaValle, G. J., Petty, L., Berens, A., Mojizisik, C., Martin, E. W., Hase, K., Shatney, C. H., Trollope, M., Johnson, D., Vierra, M., Deutsch, A. A., Tulchinsky, H., Nudelman, I., Gutman, H., Reiss, R., Taylor, Brian M., Araujo, A., Bleday, R., Jessurun, J., Heine, J., Rosen, Les, Sipe, Paul, Riether, Robert, Stasik, John, Sheets, James, Khubchandani, Indru, Reiter, W., Friedberg, G., Morey, G., Goldstein, E., Williamson, P., Larach, S., Senagore, A. J., Luchtefeld, M. A., MacKeigen, J. M., Mazier, W. P., Wengert, T., Ott, M. T., Bailey, H. R., Hartendorp, P., Dailey, T. H., Church, J. C., Johansen, O. B., Daniel, N., Korst, M., Kuijpers, H. C., Pena, J. P., Christenson, C. E., Balcos, E. G., Lewis, W., Mitchell, C., MacFie, J., Hildebrandt, U., Ecker, K. W., Kraus, J., Schmid, T., Feifel, G., Tjandra, J. J., Scoggin, Steve, Frazee, Richard C., Ambroze, Jr., W. L., Nezhat, C., Pennington, E., Nezhat, F., Stolfi, V. M., Thorson, A. G., Falk, P. M., Fitzgibbons, Jr, R. J., Luukkonen, P., Järvinen, H. J., James, E., Paty, P. B., Enker, W. E., Cohen, A. M., Lauwers, G. Y., Saad, R., Birnbaum, E., DeVos, W., Fry, R., Kodner, I., Fleshman, J., Cali, R. L., Pitsch, R. M., Blatchford, G. J., Christensen, M. A., Schroeder, T. K., Easley, K. A., Ellis, C. N., Cheape, J. D., Hull, T. L., Salanga, V., Kokoszka, Joseph, Andrianopoulos, Georgia, Nelson, Richard, Abcarian, Herand, Kumar, D., Benson, M. J., Roberts, J., Martin, J. E., Swash, M., Wingate, D. L., Williams, N. S., Orkin, B. A., Emsellem, H., Dent, John, Tissaw, M. A., Shafik, A., Abel, M. E., Chiu, Y. S. Y., Russell, T. R., Volpe, P. A., Casillas, G. L., Mashas, W. E., Eastman, D. A., Grace, R. H., Anderson, J. M., Hacker, K., Heryer, J., Conner, W., Rubin, R., Eisenstat, T., Salvati, E., Oliver, G., Duberman, E., Simmang, C. L., Fry, R. D., Kodner, I. J., Fleshman, J. W., Corman, M. L., Galandiuk, S., Weiner, G. J., Kahn, D., Mitchell, E., Abdel-Nabi, H., Block, G. E., Mannella, E., Tedesco, M., Anza, M., Civalleri, D., Di Tora, P., Capussotti, L., Morandi, G. B., Tirelli, C., Da Pian, P. P., Cortesi, E., Ruggeri, E., Fitzgerald, S. D., Davis, Faith, Bowen, Phyllis, Sutter, Eileen, Kikendall, Walter, McGannon, E., Brantley, P. A., Czyrko, C., Falardeau, C., Trepashko, Don, Skosey, John, Michelassi, F., Staniunas, R. J., Vignati, P. V., Beck, D. E., Karulf, R., Roettger, R., Braidt, J., Ruoff, K., Ackroyd, F., Shellito, P., Goh, H. S., Lin, L. W., Edwards, E., Farmer, J., Walters, C. A., Hyman, N. H., Hebert, J. C., Richman, Irving M., Staren, E. D., Sessions, S. C., Scoma, R. S., Clements, B., Smink, Jr., R. D., Arai, K., Sugita, A., Yamazaki, Y., Harada, H., Fukushima, T., Armstrong, D. N., Ballantyne, G. H., Sillin, L. F., Davie, R. J., Harding, L. K., Birch, N. J., Yamanouchi, T., Bayer, I., Mitmaker, B., Gordon, P. H., Wang, E., Kynaston, H., Edelstein, P. S., Thompson, S. M., Davies, R. J., Farmer, K. C. R., Oliver, S. E., Spigelman, A. D., Bennett, P., O'Kelly, T. J., Brading, A. F., Mortensen, N. J., Paul, P., McGannon, E. M., Huth, P., Hull-Boiner, S., Pezim, M. E., Johnson, H. W., Gillespie, K. D., Willard, P., Owen, D. A., Ramsey, P. S., Leu, S. Y., Hsu, H., Al-Humadi, Adil H., Eisman, E., Tries, J., Gupta, N. C., Frick, M. P., Boman, B. M., Franceschi, D., Eckhauser, M. L., Pritchard, T., Konsten, J., Baeten, C. G. M. I., Havenith, M. G., Soeters, P. B., Lau, P. W. K., Lorentz, T. G., Wong, J., and The III In-CYT-103 Immunoscintigraphy Study Group

Published
1992
Full Text
View/download PDF

7. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Peritoneal Surface Malignancies of Colonic Origin: A Consensus Statement

Author

Esquivel, J., Sticca, R., Sugarbaker, P., Levine, E., Yan, T. D., Alexander, R., Baratti, D., Bartlett, D., Barone, R., Barrios, P., Bieligk, S., Bretcha-Boix, P., Chang, C. K., Chu, F., Chu, Q., Daniel, S., deBree, E., Deraco, M., Dominguez-Parra, L., Elias, D., Flynn, R., Foster, J., Garofalo, A., Gilly, F. N., Glehen, O., Gomez-Portilla, A., Gonzalez-Bayon, L., Gonzalez-Moreno, S., Goodman, M., Gushchin, V., Hanna, N., Hartmann, J., Harrison, L., Hoefer, R., Kane, J., Kecmanovic, D., Kelley, S., Kuhn, J., LaMont, J., Lange, J., Li, B., Loggie, B., Mahteme, H., Mann, G., Martin, R., Misih, R. A., Moran, B., Morris, D., Onate-Ocana, L., Petrelli, N., Philippe, G., Pingpank, J., Pitroff, A., Piso, P., Quinones, M., Riley, L., Rutstein, L., Saha, S., Alrawi, S., Sardi, A., Schneebaum, S., Shen, P., Shibata, D., Spellman, J., Stojadinovic, A., Stewart, J., Torres-Melero, J., Tuttle, T., Verwaal, V., Villar, J., Wilkinson, N., Younan, R., Zeh, H., Zoetmulder, F., and Sebbag, G.

Published
2011
Full Text
View/download PDF

9. Sentinel lymph node biopsy in vulvar cancer: a multicenter evaluation of procedure's feasibility for Israeli patients.

Author

Raz, Y., Bibi, G., Ben-Arie, A., Meirovitz, M., Schneebaum, S., and Grisaru, D.

Abstract

Purpose: To evaluate the accuracy, safety, and outcome of sentinel lymph node biopsy (SLNB) in early-stage vulvar cancer and determine the applicability of this procedure for selected patients in Israel. Materials and Methods: Forty-five patients with T1 squamous cell carcinoma (SCC) of the vulva who underwent surgery with SLNB between 2002-2011 were included. SLN was detected using both radioactive tracer and blue dye. All resected nodes underwent pathological examination. The accuracy, recurrence rates, and complications of the procedure were analyzed. Results: There was a significant correlation between radioactive reading intensity and SLN detection in frozen section (p < 0.0003, p < 0.0001). A weaker correlation existed with use of blue dye (p = 0.04, p = 0.09). For metastatic LNs, the detection rates of both agents were similar. The false negative for metastatic SLN detection in frozen section was 12.5%, while the false positive was 2%. The rate of inguinal recurrence without local recurrence was 4.4%. For patients with unifocal vulvar disease and a negative sentinel node the seven-year survival rate was 94%. Conclusion: SLNB is an effective and safe procedure for Israeli patients with earlystage SCC of the vulva. Recurrence rates and disease-free survival are similar to the reported literature and morbidity is low compared to radical inguinal LNs resection. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

11. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin : a consensus statement

Author

Esquivel, J, Sticca, R, Sugarbaker, P, Levine, E, Yan, T D, Alexander, R, Baratti, D, Bartlett, D, Barone, R, Barrios, P, Bieligk, S, Bretcha-Boix, P, Chang, C K, Chu, F, Chu, Q, Daniel, S, Debree, E, Deraco, M, Dominguez-Parra, L, Elias, D, Flynn, R, Foster, J, Garofalo, A, Gilly, F N, Glehen, O, Gomez-Portilla, A, Gonzalez-Bayon, L, Gonzalez-Moreno, S, Goodman, M, Gushchin, V, Hanna, N, Hartmann, J, Harrison, L, Hoefer, R, Kane, J, Kecmanovic, D, Kelley, S, Kuhn, J, Lamont, J, Lange, J, Li, B, Loggie, B, Mahteme, Haile, Mann, G, Martin, R, Misih, R A, Moran, B, Morris, D, Onate-Ocana, L, Petrelli, N, Philippe, G, Pingpank, J, Pitroff, A, Piso, P, Quinones, M, Riley, L, Rutstein, L, Saha, S, Alrawi, S, Sardi, A, Schneebaum, S, Shen, P, Shibata, D, Spellman, J, Stojadinovic, A, Stewart, J, Torres-Melero, J, Tuttle, T, Verwaal, V, Villar, J, Wilkinson, N, Younan, R, Zeh, H, Zoetmulder, F, Sebbag, G, Esquivel, J, Sticca, R, Sugarbaker, P, Levine, E, Yan, T D, Alexander, R, Baratti, D, Bartlett, D, Barone, R, Barrios, P, Bieligk, S, Bretcha-Boix, P, Chang, C K, Chu, F, Chu, Q, Daniel, S, Debree, E, Deraco, M, Dominguez-Parra, L, Elias, D, Flynn, R, Foster, J, Garofalo, A, Gilly, F N, Glehen, O, Gomez-Portilla, A, Gonzalez-Bayon, L, Gonzalez-Moreno, S, Goodman, M, Gushchin, V, Hanna, N, Hartmann, J, Harrison, L, Hoefer, R, Kane, J, Kecmanovic, D, Kelley, S, Kuhn, J, Lamont, J, Lange, J, Li, B, Loggie, B, Mahteme, Haile, Mann, G, Martin, R, Misih, R A, Moran, B, Morris, D, Onate-Ocana, L, Petrelli, N, Philippe, G, Pingpank, J, Pitroff, A, Piso, P, Quinones, M, Riley, L, Rutstein, L, Saha, S, Alrawi, S, Sardi, A, Schneebaum, S, Shen, P, Shibata, D, Spellman, J, Stojadinovic, A, Stewart, J, Torres-Melero, J, Tuttle, T, Verwaal, V, Villar, J, Wilkinson, N, Younan, R, Zeh, H, Zoetmulder, F, and Sebbag, G

Published
2011
Full Text
View/download PDF

17. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Peritoneal Surface Malignancies of Colonic Origin: A Consensus Statement

Author

Esquivel, J., primary, Sticca, R., additional, Sugarbaker, P., additional, Levine, E., additional, Yan, T. D., additional, Alexander, R., additional, Baratti, D., additional, Bartlett, D., additional, Barone, R., additional, Barrios, P., additional, Bieligk, S., additional, Bretcha-Boix, P., additional, Chang, C. K., additional, Chu, F., additional, Chu, Q., additional, Daniel, S., additional, deBree, E., additional, Deraco, M., additional, Dominguez-Parra, L., additional, Elias, D., additional, Flynn, R., additional, Foster, J., additional, Garofalo, A., additional, Gilly, F. N., additional, Glehen, O., additional, Gomez-Portilla, A., additional, Gonzalez-Bayon, L., additional, Gonzalez-Moreno, S., additional, Goodman, M., additional, Gushchin, V., additional, Hanna, N., additional, Hartmann, J., additional, Harrison, L., additional, Hoefer, R., additional, Kane, J., additional, Kecmanovic, D., additional, Kelley, S., additional, Kuhn, J., additional, LaMont, J., additional, Lange, J., additional, Li, B., additional, Loggie, B., additional, Mahteme, H., additional, Mann, G., additional, Martin, R., additional, Misih, R. A., additional, Moran, B., additional, Morris, D., additional, Onate-Ocana, L., additional, Petrelli, N., additional, Philippe, G., additional, Pingpank, J., additional, Pitroff, A., additional, Piso, P., additional, Quinones, M., additional, Riley, L., additional, Rutstein, L., additional, Saha, S., additional, Alrawi, S., additional, Sardi, A., additional, Schneebaum, S., additional, Shen, P., additional, Shibata, D., additional, Spellman, J., additional, Stojadinovic, A., additional, Stewart, J., additional, Torres-Melero, J., additional, Tuttle, T., additional, Verwaal, V., additional, Villar, J., additional, Wilkinson, N., additional, Younan, R., additional, Zeh, H., additional, Zoetmulder, F., additional, and Sebbag, G., additional

Published
2008
Full Text
View/download PDF

18. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites

Author

Morton, D. L., primary, Mozzillo, N., additional, Thompson, J. F., additional, Kelley, M. C., additional, Faries, M., additional, Wagner, J., additional, Schneebaum, S., additional, Schuchter, L., additional, Gammon, G., additional, and Elashoff, R., additional

Published
2007
Full Text
View/download PDF

19. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Management of Peritoneal Surface Malignancies of Colonic Origin: A Consensus Statement

Author

Esquivel, J., primary, Sticca, R., additional, Sugarbaker, P., additional, Levine, E., additional, Yan, T. D., additional, Alexander, R., additional, Baratti, D., additional, Bartlett, D., additional, Barone, R., additional, Barrios, P., additional, Bieligk, S., additional, Bretcha-Boix, P., additional, Chang, C. K., additional, Chu, F., additional, Chu, Q., additional, Daniel, S., additional, de Bree, E., additional, Deraco, M., additional, Dominguez-Parra, L., additional, Elias, D., additional, Flynn, R., additional, Foster, J., additional, Garofalo, A., additional, Gilly, F. N., additional, Glehen, O., additional, Gomez-Portilla, A., additional, Gonzalez-Bayon, L., additional, Gonzalez-Moreno, S., additional, Goodman, M., additional, Gushchin, V., additional, Hanna, N., additional, Hartmann, J., additional, Harrison, L., additional, Hoefer, R., additional, Kane, J., additional, Kecmanovic, D., additional, Kelley, S., additional, Kuhn, J., additional, LaMont, J., additional, Lange, J., additional, Li, B., additional, Loggie, B., additional, Mahteme, H., additional, Mann, G., additional, Martin, R., additional, Misih, R. A., additional, Moran, B., additional, Morris, D., additional, Onate-Ocana, L., additional, Petrelli, N., additional, Philippe, G., additional, Pingpank, J., additional, Pitroff, A., additional, Piso, P., additional, Quinones, M., additional, Riley, L., additional, Rutstein, L., additional, Saha, S., additional, Alrawi, S., additional, Sardi, A., additional, Schneebaum, S., additional, Shen, P., additional, Shibata, D., additional, Spellman, J., additional, Stojadinovic, A., additional, Stewart, J., additional, Torres-Melero, J., additional, Tuttle, T., additional, Verwaal, V., additional, Villar, J., additional, Wilkinson, N., additional, Younan, R., additional, Zeh, H., additional, Zoetmulder, F., additional, and Sebbag, G., additional

Published
2006
Full Text
View/download PDF

34. Alteration of macrophage activity in experimental septic shock in the rabbit

Author

Schneebaum, S., Klein, E., Passwell, J. H., Modan, M., Kariv, N., and Ben-ari, G.

Abstract

We studied alteration in macrophage activity during experimental septic shock and the effect of the protease inhibitor Trasylol® on these alterations. Studies were carried out on three groups of 6 rabbits of each. One group (A) served as a control and in the other two groups (B, C) septic shock was induced using the cecal ligation technique. Group B received i.v. Trasylol prior to and following cecal ligation.The clearance and reticuloendothelial system (R.E.S.) distribution of 125I labelled polyvinyl pyr-rolidone (PVP) was used to study macrophage function. PVP was injected into all animals 18 h prior to cecal ligation. for 48 h following the operation, PVP blood levels were repeatedly measured and clearance calculated. The animals were then sacrificed, and total radioactivity of the various organs was measured.In the early stages after cecal ligation a significantly higher PVP clearance rate was noted in groups B and C (P < 0.01); In the later stages of the experiment, however, group C demonstrated the slowest clearance rate with intermediate values in group B. The highest PVP concentrations were found in the liver and spleen. A significantly higher PVP concentration was noted in the spleen of the animals in group A and B as compared to group C (P < 0.01) while the difference between group A and B was not significant.Our results indicate that septic shock reduces macrophage function as measured by the changes in PVP clearance and distribution. Injections of Trasylol seem to ameliorate these changes.The model of 125I PVP clearance seems to offer a convenient, valid and informative model for measurement of macrophage activity in pathological conditions.

Published
1991
Full Text
View/download PDF

35. Pilot study evaluating the intraoperative localization of radiolabeled monoclonal antibody CC83 in patients with metastatic colorectal carcinoma

Author

Burak, W.E., Schneebaum, S., Kim, J.A., Arnold, M.W., Hinkle, G., Berens, A., Mojzisik, C., and Martin, E.W.

Abstract

Background. CC83, a second-generation monoclonal antibody (MAb) against tumor-associated glycoprotein TAG-72 has been shown to have a higher affinity constant than the anti-TAG MAbs CC49 and B72.3. Clinical studies have shown the effectiveness of both CC49 and B72.3 radiolabeled MAbs in localizing colorectal carcinoma with a hand-held gamma-detecting probe during operation. This current study was designed to assess the safety and tumor-binding ability of radiolabeled CC83 MAb in this setting. Methods. Seventeen patients with recurrent colorectal cancer underwent intravenous injection with CC83 Mab radiolabeled with iodine 125 (2.0 mCi ^1^2^5I/0.2 mg CC83 MAb). Exploratory laparotomy was carried out 21 to 28 days after injection, consisting of a thorough traditional exploration followed by a survey with a hand-held gamma-detecting probe. All traditionally suspicious and probe-positive tissue was either biopsied or resected and subsequently examined for the presence of carcinoma by using routine histochemical staining techniques. Results. Thirty-two sites were identified as suspicious for cancer by traditional surgical exploration and 39 through intraoperative survey with a hand-held gamma-detecting probe in the seventeen patients completing the study. Biopsy or resection yielded 27 tumor sites when tissue was evaluated by using routine hematoxylin-eosin staining. All 27 tumor sites were localized by the radiolabeled CC83 MAb, whereas 12 additional sites were RIGS positive but hematoxylin-eosin negative, resulting in a sensitivity and positive predictive value of 100% and 69%, respectively. Traditional methods of exploration detected 23 of 27 tumor sites (85% sensitivity), and nine false-positive sites were recorded (72% positive predictive value). Occult tumor was found by using CC83 MAb in four (15%) of 27 sites, altering the surgical plan in three patients. Conclusions. This initial study indicates that CC83 MAb, when used with RIGS, is safe and sensitive in detecting recurrent intraabdominal colorectal cancer.

Published
1995
Full Text
View/download PDF

38. ICG-guided sentinel lymph node biopsy in melanoma is as effective as blue dye: A retrospective analysis.

Author

Lavy D, Shimonovitz M, Keidar D, Warshavsky A, Lessing Y, Abu-Abeid A, Schneebaum S, Miodovnik M, and Nizri E

Subjects
Humans, Retrospective Studies, Female, Male, Middle Aged, Adult, Skin Neoplasms surgery, Skin Neoplasms pathology, Aged, Follow-Up Studies, Prognosis, Image-Guided Biopsy methods, Melanoma surgery, Melanoma pathology, Melanoma diagnostic imaging, Sentinel Lymph Node Biopsy methods, Indocyanine Green, Coloring Agents
Abstract

Introduction: Sentinel lymph node biopsy (SLNB) is a key procedure in the staging and management of melanoma. Traditionally, it is performed using a dual-mapping technique combining a radioactive isotope (RI) and blue dye (BD). Fluorescence-guided surgery with indocyanine green (ICG) has emerged as an alternative tracer, offering potential advantages in real-time visualization and operative efficiency. This study compares the efficacy of RI + ICG with RI + BD in SLNB for melanoma., Methods: We conducted a retrospective cohort study at a single center, including 311 patients who underwent SLNB for melanoma. Patients were divided into two groups: RI + BD (n = 227, January 2010-August 2022) and RI + ICG (n = 84, August 2022-February 2024). SLN detection rates, positive SLN rates, operative times, and postoperative complications were compared between the two groups., Results: Both groups were clinically and pathologically comparable. SLN detection rates were 100 % in the RI + BD group and 98.8 % in the RI + ICG group (p = 0.1). The median number of lymph nodes resected was lower in the RI + ICG group as compared to the RI + BD group (p = 0.047). While positive SLN rates were higher in the RI + ICG group (9.5 % vs. 6.2 %), this difference was not statistically significant (p = 0.3). ICG alone could not identify all the positive SLN. Postoperative complications, including seroma, did not differ significantly between groups., Conclusions: ICG-guided SLNB is comparable to BD-guided SLNB in terms of detection rate and SLN positivity, although it can not be used alone to identify all positive SLNBs. ICG-based fluorescence imaging is a promising technique that may enhance surgical efficiency in melanoma management., (Copyright © 2024. Published by Elsevier Ltd.)

Published
2024
Full Text
View/download PDF

39. Long-term outcomes and patterns of recurrence in patients with thin melanoma and a negative sentinel lymph node biopsy: a single-center experience.

Author

Shemer M, Shimonovitz M, Furer R, Abu-Abeid A, Dayan D, Schneebaum S, Miodovnik M, and Nizri E

Subjects
Humans, Female, Male, Middle Aged, Adult, Retrospective Studies, Aged, Aged, 80 and over, Young Adult, Melanoma pathology, Sentinel Lymph Node Biopsy methods, Skin Neoplasms pathology, Neoplasm Recurrence, Local pathology
Abstract

The majority of patients diagnosed with melanoma have thin melanomas (≤1 mm). Data on the rate and pattern of recurrence after a negative sentinel lymph node biopsy (SLNB) are sparse. We retrospectively searched our institutional database and retrieved the records of patients with thin melanomas who underwent an SLNB with negative results. We analyzed patterns of recurrence, time to recurrence, and mode of diagnosis. Thirteen of the 198 patients with thin melanomas and negative SLNB results had tumor recurrence (6.5%): two local in transit (15.4%), three regional (21.3%), and eight distant (61.5%). Distant recurrences tended to occur later than local or regional ones [median disease-free survival = 50 months (95% confidence interval: 36.1-63.9) vs. 34 and 15 months (95% confidence interval: 5.4-24.6), P  = 0.005, respectively]. The percentage of patients with tumor thickness ≥0.8 mm was higher among those who sustained recurrence (84.6 vs. 64.9% for no recurrence, P  = 0.04). The majority of patients with recurrence were not being followed up when diagnosed (69%), and they are presented because of clinical symptoms. Patients with recurrence had lower survival compared with those without recurrence (median: 118 months vs. ongoing survival, P  < 0.001, respectively). Melanoma recurrence in patients with thin melanomas and negative SLNBs is rare, tends to be distant, and negatively affects prognosis. Recurrence tends to occur in patients with melanoma thickness ≥0.8 mm. Further studies are needed to identify patients with high recurrence risk and determine optimal follow-up protocols., (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2024
Full Text
View/download PDF

40. Current Challenges and Perspectives in Breast Cancer in Elderly Women: The Senologic International Society (SIS) Survey.

Author

Scheer L, Lodi M, Özmen T, Alghamdi K, Anyanwu S, Birendra J, Boubnider M, Costa M, Dian D, Elder E, Gebrim LH, Guo X, Heitz D, Imoto S, Ioannidou-Mouzaka L, Kaufman C, Liu H, Mbodj M, Meka E, Mundinger A, Novelli J, Ojuka D, Orda R, Ostapenko V, Pieńkowski T, Podolski P, Vogel T, Yin J, Özmen V, Schneebaum S, and Mathelin C

Abstract

Objective: Mammographic screening and management of breast cancer (BC) in elderly women are controversial and continue to be an important health problem. To investigate, through members of the Senologic International Society (SIS), the current global practices in BC in elderly women, highlighting topics of debate and suggesting perspectives., Materials and Methods: The questionnaire was sent to the SIS network and included 55 questions on definitions of an elderly woman, BC epidemiology, screening, clinical and pathological characteristics, therapeutic management in elderly women, onco-geriatric assessment and perspectives., Results: Twenty-eight respondents from 21 countries and six continents, representing a population of 2.86 billion, completed and submitted the survey. Most respondents considered women 70 years and older to be elderly. In most countries, BC was often diagnosed at an advanced stage compared to younger women, and age-related mortality was high. For this reason, participants recommended that personalized screening be continued in elderly women with a long life expectancy.In addition, this survey highlighted that geriatric frailty assessment tools and comprehensive geriatric evaluations needed to be used more and should be developed to avoid undertreatment. Similarly, multidisciplinary meetings dedicated to elderly women with BC should be encouraged to avoid under- and over-treatment and to increase their participation in clinical trials., Conclusion: Due to increased life expectancy, BC in elderly women will become a more important field in public health. Therefore, screening, personalized treatment, and comprehensive geriatric assessment should be the cornerstones of future practice to avoid the current excess of age-related mortality. This survey described, through members of the SIS, a global picture of current international practices in BC in elderly women., Competing Interests: Conflict of Interest: No conflict of interest was declared by the authors., (©Copyright 2023 by the the Turkish Federation of Breast Diseases Societies / European Journal of Breast Health published by Galenos Publishing House.)

Published
2023
Full Text
View/download PDF

41. Regarding: Predicting Regional Lymph Node Recurrence in The Modern Age of Tumor-Positive Sentinel Node Melanoma.

Author

Thompson JF, Hyngstrom J, Caracò C, Zager JS, Jahkola T, Bowles TL, Pennacchioli E, Hoekstra HJ, Moncrieff M, Ingvar C, van Akkooi A, Sabel MS, Levine EA, Henderson M, Dummer R, Rossi CR, Kane JM 3rd, Trocha S, Wright F, Byrd DR, Matter M, MacKenzie-Ross A, Kelley MC, Terheyden P, Huston TL, Wayne JD, Neuman H, Smithers BM, Desai D, Gershenwald JE, Schneebaum S, Gesierich A, Jacobs LK, Lewis JM, O'Donoghue C, Sardi A, McKinnon JG, Slingluff CL, Farma JM, Schultz E, Scheri RP, Vidal-Sicart S, Testori AAE, Scolyer RA, Elashoff DE, Cochran AJ, and Faries MB

Subjects
Humans, Lymph Nodes surgery, Lymph Nodes pathology, Sentinel Lymph Node Biopsy, Lymph Node Excision, Melanoma surgery, Melanoma pathology, Skin Neoplasms surgery, Skin Neoplasms pathology
Published
2023
Full Text
View/download PDF

42. Therapeutic Value of Sentinel Lymph Node Biopsy in Patients With Melanoma: A Randomized Clinical Trial.

Author

Crystal JS, Thompson JF, Hyngstrom J, Caracò C, Zager JS, Jahkola T, Bowles TL, Pennacchioli E, Beitsch PD, Hoekstra HJ, Moncrieff M, Ingvar C, van Akkooi A, Sabel MS, Levine EA, Agnese D, Henderson M, Dummer R, Neves RI, Rossi CR, Kane JM 3rd, Trocha S, Wright F, Byrd DR, Matter M, Hsueh EC, MacKenzie-Ross A, Kelley M, Terheyden P, Huston TL, Wayne JD, Neuman H, Smithers BM, Ariyan CE, Desai D, Gershenwald JE, Schneebaum S, Gesierich A, Jacobs LK, Lewis JM, McMasters KM, O'Donoghue C, van der Westhuizen A, Sardi A, Barth R, Barone R, McKinnon JG, Slingluff CL, Farma JM, Schultz E, Scheri RP, Vidal-Sicart S, Molina M, Testori AAE, Foshag LJ, Van Kreuningen L, Wang HJ, Sim MS, Scolyer RA, Elashoff DE, Cochran AJ, and Faries MB

Subjects
Female, Humans, Lymph Node Excision, Lymphatic Metastasis, Male, Prognosis, Sentinel Lymph Node Biopsy methods, Melanoma pathology, Skin Neoplasms pathology, Skin Neoplasms surgery
Abstract

Importance: Sentinel lymph node (SLN) biopsy is a standard staging procedure for cutaneous melanoma. Regional disease control is a clinically important therapeutic goal of surgical intervention, including nodal surgery., Objective: To determine how frequently SLN biopsy without completion lymph node dissection (CLND) results in long-term regional nodal disease control in patients with SLN metastases., Design, Setting, and Participants: The second Multicenter Selective Lymphadenectomy Trial (MSLT-II), a prospective multicenter randomized clinical trial, randomized participants with SLN metastases to either CLND or nodal observation. The current analysis examines observation patients with regard to regional nodal recurrence. Trial patients were aged 18 to 75 years with melanoma metastatic to SLN(s). Data were collected from December 2004 to April 2019, and data were analyzed from July 2020 to January 2022., Interventions: Nodal observation with ultrasonography rather than CLND., Main Outcomes and Measures: In-basin nodal recurrence., Results: Of 823 included patients, 479 (58.2%) were male, and the mean (SD) age was 52.8 (13.8) years. Among 855 observed basins, at 10 years, 80.2% (actuarial; 95% CI, 77-83) of basins were free of nodal recurrence. By univariable analysis, freedom from regional nodal recurrence was associated with age younger than 50 years (hazard ratio [HR], 0.49; 95% CI, 0.34-0.70; P < .001), nonulcerated melanoma (HR, 0.36; 95% CI, 0.36-0.49; P < .001), thinner primary melanoma (less than 1.5 mm; HR, 0.46; 95% CI, 0.27-0.78; P = .004), axillary basin (HR, 0.61; 95% CI, 0.44-0.86; P = .005), fewer positive SLNs (1 vs 3 or more; HR, 0.32; 95% CI, 0.14-0.75; P = .008), and SLN tumor burden (measured by diameter less than 1 mm [HR, 0.39; 95% CI, 0.26-0.60; P = .001] or less than 5% area [HR, 0.36; 95% CI, 0.24-0.54; P < .001]). By multivariable analysis, younger age (HR, 0.57; 95% CI, 0.39-0.84; P = .004), thinner primary melanoma (HR, 0.40; 95% CI, 0.22-0.70; P = .002), axillary basin (HR, 0.55; 95% CI, 0.31-0.96; P = .03), SLN metastasis diameter less than 1 mm (HR, 0.52; 95% CI, 0.33-0.81; P = .007), and area less than 5% (HR, 0.58; 95% CI, 0.38-0.88; P = .01) were associated with basin control. When looking at the identified risk factors of age (50 years or older), ulceration, Breslow thickness greater than 3.5 mm, nonaxillary basin, and tumor burden of maximum diameter of 1 mm or greater and/or metastasis area of 5% or greater and excluding missing value cases, basin disease-free rates at 5 years were 96% (95% CI, 88-100) for patients with 0 risk factors, 89% (95% CI, 82-96) for 1 risk factor, 86% (95% CI, 80-93) for 2 risk factors, 80% (95% CI, 71-89) for 3 risk factors, 61% (95% CI, 48-74) for 4 risk factors, and 54% (95% CI, 36-72) for 5 or 6 risk factors., Conclusions and Relevance: This randomized clinical trial was the largest prospective evaluation of long-term regional basin control in patients with melanoma who had nodal observation after removal of a positive SLN. SLN biopsy without CLND cleared disease in the affected nodal basin in most patients, even those with multiple risk factors for in-basin recurrence. In addition to its well-validated value in staging, SLN biopsy may also be regarded as therapeutic in some patients., Trial Registration: ClinicalTrials.gov Identifier: NCT00297895.

Published
2022
Full Text
View/download PDF

43. The Senologic International Society Survey on Ductal Carcinoma In Situ : Present and Future.

Author

Mathelin C, Lodi M, Alghamdi K, Arboleda-Osorio B, Avisar E, Anyanwu S, Boubnider M, Costa MM, Elder E, Elonge T, Gebrim L, Hao X, Imoto S, Meka E, Mouelle M, Mundinger A, Ostapenko V, Özbaş S, Özmen T, Özmen V, Pienkowski T, Sarria G, Selim A, Semiglazov V, and Schneebaum S

Abstract

Objective: Therapeutic management of ductal carcinoma in situ (DCIS) is heterogeneous among countries worldwide, and some treatment indications are still controversial. To investigate DCIS management in different countries; identify both consensual practices and controversial topics; and survey opinions about the future management of DCIS., Materials and Methods: The Senologic International Society network members participated to an online survey using a questionnaire, between November 2021 and February 2022., Results: Twenty-two responses from 20 different countries showed that organized breast cancer screening programs were present for 87% participants, and DCIS cases represented 13.7% of all breast cancers. Most participants used the grade classification (100%), the morphological classification (78%) and performed immunohistochemistry assays (73%). In case of conservative treatment, the mean re-excision rate was 10.3% and clear margins of mean 2.5 mm were considered healthy. Radical mastectomy rate was 35.5% with a breast reconstruction rate of 53%. Tumor bed boost indications were heterogeneous, and 73% of participants indicated hormone therapy for hormone-positive DCIS. Surgery and radiotherapy omission for some low-risk DCIS were considered by 73% of participants. Multigene assays were used by 43% of participants. Concerning future changes in DCIS management, participants mostly answered surgical de-escalation (48%), radiotherapy de-escalation (35) and/or active surveillance for some cases (22%)., Conclusion: This survey provided an overview of the current practices of DCIS management worldwide. It showed that some areas are rather consensual: incidence increases over time, treatment in young women, pathological classifications, definition of healthy margins, the skin-sparing mastectomy and immediate breast reconstruction. However, some topics are still debated and result in heterogeneous practices, such as evolution in the age of diagnosis, the benefit of de-escalation in low-risk DCIS among elderly women, indications for hormone therapy, radiotherapy omission, or multigene assays. Further evidence is needed to reach consensus on these points, and innovative approaches are still under evaluation in clinical trials. The International Senologic Society, by its members, encourages precision medicine and personalized treatments for DCIS, to avoid overtreatment and overdiagnosis, and provide better healthcare to women with DCIS., Competing Interests: Conflict of Interest: No conflict of interest was declared by the authors., (©Copyright 2022 by the the Turkish Federation of Breast Diseases Societies / European Journal of Breast Health published by Galenos Publishing House.)

Published
2022
Full Text
View/download PDF

44. Is There a Relationship Between TILs and Regression in Melanoma?

Author

Morrison S, Han G, Elenwa F, Vetto JT, Fowler G, Leong SP, Kashani-Sabet M, Pockaj B, Kosiorek HE, Zager JS, Messina JL, Mozzillo N, Schneebaum S, and Han D

Subjects
Humans, Lymphatic Metastasis pathology, Lymphocytes, Tumor-Infiltrating pathology, Prognosis, Sentinel Lymph Node Biopsy, Lymphadenopathy, Melanoma pathology, Skin Neoplasms pathology
Abstract

Background: The relationship between tumor-infiltrating lymphocytes (TILs) and regression in melanoma is unknown. This report describes a large multicenter study assessing the association between TILs and regression., Methods: The Sentinel Lymph Node Working Group database was queried from 1993 to 2018 for cases with TILs and regression data. Clinicopathologic factors were correlated with regression and TIL status, sentinel lymph node (SLN) status, and overall survival (OS)., Results: The study enrolled 2450 patients. In 1811 cases, TILs (73.9%) were present, with regression present in 328 of these 1811 (18.1%) cases and in 49 (7.7%) of 639 cases without TILs. The presence of TILs was significantly associated with regression (p < 0.0001) as well as a negative SLN (p < 0.05). However, when TILs were stratified by regression status, only absence or presence of both TILs and regression were significantly associated with SLN metastases (p = 0.038). Although the presence of TILs was associated with OS (p < 0.05), regression status by itself was not (p = 0.2058 and 0.252, respectively). Furthermore, when TILs were stratified by regression status, only the presence of TILs with or without regression was significantly associated with improved OS (p = 0.0081 and 0.0137, respectively) versus the absence of both TILs and regression, with regression status not significantly affecting OS for patients with or without TILs (p = 0.2314 and 0.65, respectively)., Conclusions: Regression is highly correlated with TILs, but only TILs are significantly associated with SLN metastasis and OS in melanoma patients, whereas regression is not. The impact of regression on outcomes ultimately appears dependent upon the absence or presence of TILs., (© 2022. Society of Surgical Oncology.)

Published
2022
Full Text
View/download PDF

45. Is the presence of tumor-infiltrating lymphocytes predictive of outcomes in patients with melanoma?

Author

Morrison SL, Han G, Elenwa F, Vetto JT, Fowler G, Leong SP, Kashani-Sabet M, Pockaj BA, Kosiorek HE, Zager JS, Sondak VK, Messina JL, Mozzillo N, Schneebaum S, and Han D

Subjects
Humans, Lymphocytes, Tumor-Infiltrating, Prognosis, Retrospective Studies, Sentinel Lymph Node Biopsy, Melanoma pathology, Skin Neoplasms pathology
Abstract

Background: The significance of tumor-infiltrating lymphocytes (TILs) in melanoma is debated. This article presents a multicenter, retrospective study assessing the predictive and prognostic value of TILs., Methods: The Sentinel Lymph Node Working Group database was queried from 1993 to 2018 for cases with known TIL data. TILs were categorized as absent or present, which included nonbrisk (NB), brisk (B), and present but unspecified TIL levels. Clinicopathologic factors were correlated with TILs, sentinel lymph node (SLN) status, and melanoma-specific survival (MSS)., Results: Overall, 3203 patients were included. The median thickness was 1.5 mm, and 469 cases had SLN metastases. TILs were present in 2458 cases (76.7%), with NB, B, and unspecified TILs seen in 1691 (68.8%), 691 (28.1%), and 76 (3.1%), respectively. Multivariable analysis showed that the presence of TILs significantly predicted a negative SLN biopsy (P < .05). The median follow-up was 25.2 months. MSS was significantly better for cases with TILs than cases without TILs (P < .001). According to multivariable analysis, age, gender, thickness, mitotic rate, ulceration, lymphovascular invasion, and SLN status were significantly prognostic of MSS (all P values < .05). Although TILs were not prognostic of MSS, when multiple imputation was used and the SLN status was excluded, the presence of TILs was significantly prognostic of improved MSS (hazard ratio, 0.78; 95% confidence interval, 0.64-0.95; P = .0154)., Conclusions: TILs are a favorable marker because their presence significantly predicts a negative SLN, and the absence of TILs may be a prognostic marker of worse survival in patients with a positive SLN but not a negative SLN. TILs may also serve as a prognostic marker of survival when the SLN status is not considered., (© 2022 American Cancer Society.)

Published
2022
Full Text
View/download PDF

46. The Benefit of Routine Axillary Sonographic Assessment in cN0 Breast Cancer Patients.

Author

Khatib M, Sgardelis P, Schneebaum S, Schaffer O, and Sutton R

Abstract

Objective: Axillary ultrasound (US) is often part of the routine assessment of the clinically negative axilla in primary breast cancer, which determines the extent of axillary surgery to be performed. This study aims to ascertain the burden of disease in the axilla of patients with a normal clinical examination (cN0) but with US detected metastatic axillary lymph nodes., Materials and Methods: We retrospectively identified 345 female patients who underwent axillary lymph node dissection, following a positive lymph node biopsy, between January 2015 and August 2019.Eighty-nine of those had a positive biopsy prior to surgery. They were divided into two groups: Those with clinically palpable axillary disease preoperatively, cN1 (n = 41), and those with a normal clinical axillary examination, cN0 (n = 48). We assessed the number of positive axillary lymph nodes dissected in the two groups., Results: In the cN0 group the mean value of excised disease-positive axillary lymph nodes was 3.6, while in the cN1 group it was 8.0 ( p <0.01). However, further analysis showed that 25 patients of the cN0 who had T1/T2 tumors had ≥3 positive lymph nodes., Conclusion: Our study suggests that the presence of clinically palpable axillary lymph nodes appears to be correlated to a higher number of positive lymph nodes. However, in cases of non-palpable sonographically positive lymph nodes there might still be significant axillary disease, even in T1 and T2 tumors. Therefore we still support the routine use of preoperative sonographic assessment of the axilla for early breast cancer., Competing Interests: Conflict of Interest: No conflict of interest was declared by the authors., (©Copyright 2022 by the the Turkish Federation of Breast Diseases Societies / European Journal of Breast Health published by Galenos Publishing House.)

Published
2022
Full Text
View/download PDF

47. [CURRENT ASPECTS OF BREAST CANCER TREATMENT].

Author

Schneebaum S

Subjects
Female, Humans, Israel epidemiology, Breast Neoplasms diagnosis, Breast Neoplasms therapy, Surgeons
Abstract

Introduction: Breast cancer is the most common malignant tumor in Israel and the Western World. Approximately 5,000 women are being diagnosed with breast cancer every year in Israel. Treatment of breast cancer has changed from surgical only to multidisciplinary including surgeons, oncologists, radiologists and plastic surgeons.

Published
2022

48. Regression in melanoma is significantly associated with a lower regional recurrence rate and better recurrence-free survival.

Author

Subramanian S, Han G, Olson N, Leong SP, Kashani-Sabet M, White RL, Zager JS, Sondak VK, Messina JL, Pockaj B, Kosiorek HE, Vetto J, Fowler G, Schneebaum S, and Han D

Subjects
Aged, Female, Humans, Lymphatic Metastasis, Male, Melanoma pathology, Middle Aged, Sentinel Lymph Node pathology, Sentinel Lymph Node surgery, Melanoma mortality, Neoplasm Recurrence, Local epidemiology
Abstract

Background and Objectives: The prognostic significance of regression in predicting melanoma recurrences is unknown. We present a large multicenter study correlating regression with recurrence., Methods: The Sentinel Lymph Node Working Group database was queried from 1993 to 2018 for cases with regression data. Clinicopathologic factors were correlated with overall and first-site of recurrence and with recurrence-free survival (RFS)., Results: There were 4790 patients and the median follow-up was 39.6 months. Regression and recurrences were seen in 1081 (22.6%) and 773 (16.1%) cases, respectively. First-site locoregional and distant recurrences were seen in 412 (8.6%) and 352 (7.3%) patients, respectively. Regression was seen in 15.8% and 24.7% of all cases with and without recurrences (p < 0.0001), respectively, while regression was seen in 14.3% and 17.9% of first-site locoregional and distant recurrent cases, respectively, compared with 23.3% and 22.9% of patients with regression and without first-site locoregional and distant recurrences, respectively (p = 0.29). On multivariable analysis, after controlling for age, gender, thickness, ulceration, lymphovascular invasion, and sentinel lymph node status, regression significantly predicted improved RFS (p = 0.004) and fewer first-site regional recurrences (p = 0.017)., Conclusion: Our data suggest that regression is a favorable prognostic marker in melanoma and predicts significantly better RFS and decreased first-site regional recurrences., (© 2021 Wiley Periodicals LLC.)

Published
2022
Full Text
View/download PDF

49. Regression is significantly associated with outcomes for patients with melanoma.

Author

Subramanian S, Han G, Olson N, Leong SP, Kashani-Sabet M, White RL, Zager JS, Sondak VK, Messina JL, Pockaj B, Kosiorek HE, Vetto J, Fowler G, Schneebaum S, and Han D

Subjects
Aged, Female, Humans, Lymphatic Metastasis, Male, Melanoma pathology, Middle Aged, Retrospective Studies, Melanoma mortality, Neoplasm Regression, Spontaneous
Abstract

Background: The prognostic significance of regression in melanoma is debated. We present a large multicenter study correlating regression with sentinel lymph node metastasis and melanoma-specific survival., Methods: The Sentinel Lymph Node Working Group database was reviewed from 1993 to 2018. Patients with known regression and sentinel lymph node status were included. Clinicopathologic factors were correlated with regression, sentinel lymph node status, and melanoma-specific survival., Results: There were 4,790 patients; median follow-up was 39.6 months. Regression was present in 1,081 (22.6%) cases, and 798 (16.7%) patients had sentinel lymph node metastases. On multivariable analysis, male sex, truncal tumors, and decreasing thickness were significantly associated with regression (P < .05), whereas head/neck or leg tumors had lower rates of regression (P < .05). Regression was significantly correlated with a decreased risk of sentinel lymph node disease on multivariable analysis (odds ratio 0.68, 95% confidence interval 0.54-0.85; P = .0008). Multivariable analysis also showed that increasing age, male sex, increasing thickness, ulceration, lymphovascular invasion, microsatellitosis, and sentinel lymph node metastasis were significantly (P < .05) associated with worse melanoma-specific survival, while regression was significantly associated with better melanoma-specific survival (hazard ratio 0.75, 95% confidence interval 0.57-0.99; P = .043)., Conclusion: This large study shows that regression is significantly associated with better outcomes in patients with melanoma and is correlated with a lower risk of sentinel lymph node metastasis and a better melanoma-specific survival., (Copyright © 2021 Elsevier Inc. All rights reserved.)

Published
2021
Full Text
View/download PDF

50. Preoperative Ultrasound Assessment of Regional Lymph Nodes in Melanoma Patients Does not Provide Reliable Nodal Staging: Results From a Large Multicenter Trial.

Author

Thompson JF, Haydu LE, Uren RF, Andtbacka RH, Zager JS, Beitsch PD, Agnese DM, Mozzillo N, Testori A, Bowles TL, Hoekstra HJ, Kelley MC, Sussman J, Schneebaum S, Smithers BM, McKinnon G, Hsueh E, Jacobs L, Schultz E, Reintgen D, Kane JM, Friedman EB, Wang H, Van Kreuningen L, Schiller V, Elashoff DA, Elashoff R, Cochran AJ, Stern S, and Faries MB

Subjects
Follow-Up Studies, Humans, Lymphatic Metastasis, Melanoma secondary, Melanoma surgery, Retrospective Studies, Skin Neoplasms surgery, Lymph Node Excision, Lymph Nodes diagnostic imaging, Melanoma diagnosis, Neoplasm Staging methods, Preoperative Care methods, Skin Neoplasms diagnosis, Ultrasonography methods
Abstract

Objective: To assess whether preoperative ultrasound (US) assessment of regional lymph nodes in patients who present with primary cutaneous melanoma provides accurate staging., Background: It has been suggested that preoperative US could avoid the need for sentinel node (SN) biopsy, but in most single-institution reports, the sensitivity of preoperative US has been low., Methods: Preoperative US data and SNB results were analyzed for patients enrolled at 20 centers participating in the screening phase of the second Multicenter Selective Lymphadenectomy Trial. Excised SNs were histopathologically assessed and considered positive if any melanoma was seen., Results: SNs were identified and removed from 2859 patients who had preoperative US evaluation. Among those patients, 548 had SN metastases. US was positive (abnormal) in 87 patients (3.0%). Among SN-positive patients, 39 (7.1%) had an abnormal US. When analyzed by lymph node basin, 3302 basins were evaluated, and 38 were true positive (1.2%). By basin, the sensitivity of US was 6.6% (95% confidence interval: 4.6-8.7) and the specificity 98.0% (95% CI: 97.5-98.5). Median cross-sectional area of all SN metastases was 0.13 mm2; in US true-positive nodes, it was 6.8 mm2. US sensitivity increased with increasing Breslow thickness of the primary melanoma (0% for ≤1 mm thickness, 11.9% for >4 mm thickness). US sensitivity was not significantly greater with higher trial center volume or with pre-US lymphoscintigraphy., Conclusion: In the MSLT-II screening phase population, SN tumor volume was usually too small to be reliably detected by US. For accurate nodal staging to guide the management of melanoma patients, US is not an effective substitute for SN biopsy., Competing Interests: The authors report no conflicts of interest, (Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results